Key Takeaways
- The FDA advisory committee delivered a 7-2 vote indicating Grail’s Galleri test benefits exceed potential risks.
- Safety received unanimous approval (10-0), while effectiveness passed with a 6-4 vote from the panel.
- Shares of Grail surged 36% during the past week, reaching approximately $108 per share.
- Canaccord Genuity maintained its Buy recommendation and increased its target price post-hearing.
- Complete FDA clearance may be granted in the coming months.
Grail (GRAL) shares are currently hovering around $108 following a crucial FDA advisory panel endorsement of its Galleri multicancer blood screening technology earlier this week. The equity gained 36% throughout the past week, with the majority of gains materializing during the two trading sessions preceding Wednesday’s panel meeting.
On Wednesday, the Molecular and Clinical Genetics Devices Panel convened to evaluate Galleri. Panel members delivered a 7-2 vote, with one member abstaining, supporting the conclusion that the diagnostic tool’s advantages outweigh potential drawbacks.
The safety assessment received full unanimous support with a 10-0 tally. The effectiveness determination proved more contentious, passing with a 6-4 vote.
Grail shares remained halted throughout the entire trading session during the panel’s deliberations. The stock had already experienced substantial gains following the release of positive briefing materials online on Monday.
While complete FDA authorization isn’t certain, the probability appears strong given the hearing’s outcome. Industry analysts anticipate a regulatory determination within the next several months.
Understanding Galleri’s Functionality
Galleri analyzes blood samples to detect DNA fragments bearing cancer cell signatures. The test identifies whether a cancer signal exists anywhere within the body and provides an estimation of the signal’s origin.
Clinical research demonstrated Galleri’s capability to identify malignancies lacking conventional screening methods, such as ovarian and pancreatic cancers. The technology produces false positives infrequently, though its detection rate stands at approximately 50% when cancer is actually present.
This detection performance compares favorably against established tools such as mammography. Grail envisions patients utilizing Galleri alongside current single-cancer screening protocols rather than as a replacement.
However, one clinical trial presents a complication. The NHS-Galleri research conducted in Britain failed to demonstrate that screening reduced the quantity of Stage IV cancers identified one year later.
Several panel members expressed that this shortfall created uncertainty regarding whether Galleri extends lives. Notably, numerous screening technologies currently in widespread adoption, such as colonoscopies, received acceptance before long-term survival evidence validated their effectiveness.
Revenue Projections and Expert Commentary
Grail currently markets Galleri at $950 per test, though insurance reimbursement remains uncommon. The organization recorded approximately $150 million in revenue last year, with projections for this year reaching $180 million.
Mizuho analyst Bradley Bowers anticipates a more substantial increase following regulatory approval. He referenced comparable cancer-screening products, including Cologuard and Guardant Health’s Shield diagnostic, both experiencing revenue doubling during their respective launch periods.
Legislative action has already mandated Medicare to evaluate coverage for diagnostics like Galleri once FDA authorization occurs. UBS analyst Doug Schenkel projects Medicare reimbursement beginning in 2029 could contribute approximately $300 million to Grail’s annual revenue the subsequent year, elevating total sales toward the $1 billion threshold.
Canaccord Genuity reaffirmed its Buy stance on Grail Wednesday and characterized the hearing as exceeding expectations. The firm interprets the panel’s benefit-risk vote as a robust indicator for eventual authorization.
Grail currently commands a $4.3 billion market capitalization, representing roughly 19 times projected next-year revenue. This valuation already incorporates a substantial probability of approval.
InvestingPro data indicates the equity trading above the platform’s fair value calculation, with an RSI measurement suggesting overbought territory following the recent rally. Grail isn’t anticipated to achieve profitability this year.
During its latest quarterly report, Grail disclosed revenue of $44.7 million, surpassing the $43.2 million analyst consensus, while posting a per-share loss of $2.56. Canaccord is conducting a webcast Friday featuring two cancer screening specialists to analyze the panel’s conclusions and discuss upcoming developments.
The post Grail (GRAL) Stock Surges 36% Following Positive FDA Advisory Panel Vote on Galleri Test appeared first on Blockonomi.
